Psoriasis

RESEARCH STUDY FOR NAIL AND BODY PSORIASIS (76 WEEKS)

Adults aged 18 years or older with moderate to severe nail and body psoriasis, may qualify to receive investigational medication (active study drug) or placebo, via subcutaneous injection.

To be eligible, participants must have chronic, moderate to severe plaque-type psoriasis for at least 6 months. Psoriatic involvement of 10% or more body surface area (BSA) is required in addition to nail involvement/psoriasis. Participants must be considered candidates for systemic therapy, meaning psoriasis is inadequately controlled by topical treatments (corticosteroids), and/or phototherapy, and/or previous systemic therapy. Eligible participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.

Individuals will be asked to visit the study centre about 15 times over a period of about 76 weeks.

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis – Full Text View – ClinicalTrials.gov

For more information, please contact:

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Jackie Nguyen
t: 9623 9464
e: [email protected]

Study Coordinator
Irina Danilovich
t: 9623 9448
e: [email protected]

PLAQUE PSORIASIS TRIAL (20 WEEKS)

Adults from 18 to 70 years of age with a documented clinical diagnosis of plaque psoriasis (PsO) for at least 6 months, may qualify for this clinical research trial and receive investigational oral medication
(active study drug) or placebo via tablets.

Eligible participants must have psoriatic plaques covering 10% or more of their body surface area (BSA), roughly equivalent in area to the size of 10 palm prints. Participants must also have a body weight >50kg and a body mass index (BMI) of 18-40kg/m2.

Participants also need to be willing to discontinue topical and systemic therapies (with the exception of topical emollients and low potency
topical steroids). Participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.

Individuals will be asked to visit the study centre about 9 times over a period of about 20 weeks.

Study to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis. ClinicalTrials.gov

For more information, please contact:

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Jackie Nguyen
t: 9623 9464
e: [email protected]

Study Coordinator
Tracy Mallett
t: 9623 9400
e: [email protected]

Scroll to Top